Management of Deep Vein Thrombosis During Pregnancy

Initial Treatment

The American College of Cardiology recommends low-molecular-weight heparin (LMWH) over unfractionated heparin (UFH) for the treatment of acute DVT in pregnant women due to its superior efficacy profile, consistent therapeutic levels, and lower risk of complications 1, 2
For pregnant women with acute DVT, either once-daily or twice-daily LMWH dosing regimens can be used, based on individual patient factors 1, 3
Initial outpatient therapy with LMWH is appropriate for pregnant women with low-risk acute DVT when proper support services are available 1, 4
Routine monitoring of anti-factor Xa levels to guide LMWH dosing is not recommended unless there are specific concerns about therapeutic levels 1, 2

The American College of Physicians recommends that therapeutic anticoagulation should be maintained throughout pregnancy and for at least 6 weeks postpartum (for a minimum total duration of 3 months) 5, 6
Vitamin K antagonists (warfarin/Coumadin) should be avoided during pregnancy as they cross the placenta and are associated with embryopathy between 6-12 weeks' gestation and fetal bleeding at delivery 6, 7
Neither LMWH nor unfractionated heparin crosses the placenta, making them safe options during pregnancy 6, 8

For pregnant women receiving therapeutic-dose LMWH for DVT management, scheduled delivery with prior discontinuation of anticoagulant therapy (typically 24 hours before anticipated delivery) is suggested 1, 2
In the postpartum period, either continuation of LMWH or transition to warfarin is appropriate 5

Compression stockings should be used starting within 1 month of DVT diagnosis and continuing for at least 1 year to prevent postthrombotic syndrome 5, 7
For pregnant women with severe DVT complications (such as pulmonary embolism with hemodynamic instability), additional interventions including systemic thrombolytic therapy may be considered 1, 2
Vena cava filters may be considered in very select cases where anticoagulation is contraindicated or has failed, though evidence supporting their use in pregnancy is limited 9, 10

The 10-day intravenous heparin followed by Coumadin regimen should be avoided due to the teratogenic effects of warfarin 6, 7
The 10-day intravenous heparin followed by prophylactic subcutaneous heparin provides inadequate anticoagulation for established DVT 1